Drugs / IPS101A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07371338 | May 2026 → Oct 2027 expected | Parkinson disease | Innopeutics Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Innopeutics Corporation | Regulatory 파킨슨병 유전자치료제 1상 임상시험 승인 innopeutics.com ↗
이노퓨틱스의 아데노 부속 바이러스(AAV) 벡터 기반 파킨슨병 유전자치료제 (IPS101A)가 2025. 9. 17. 식품의약품안전처로부터 1상 임상시험 승인을 받았습니다. |
| 2025-09-18 | EyeGene Inc. | Regulatory 이노퓨틱스, 파킨슨병 유전자치료제 1상 임상시험 승인 eyegene.co.kr ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Innopeutics Corporation | 파킨슨병 유전자치료제 1상 임상시험 승인 innopeutics.com ↗ |
| 2025-09-18 | EyeGene Inc. | 이노퓨틱스, 파킨슨병 유전자치료제 1상 임상시험 승인 eyegene.co.kr ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPS101A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371338 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus (AAV) gene therapy” NCT07371338 ↗ |
| Route | Other | “stereotactic injections into the left and right substantia nigra of the midbrain” NCT07371338 ↗ |